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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not is 
metoclopramide effective in treating symptoms in diabetic gastroparesis? 
 
Study Design: Systematic review of 1 controlled randomized double blinded study, 1controlled 
randomized open label study, and 1 controlled open label case analysis published in peer 
reviewed journals between 2012-2014, all in English language.  
 
Data Sources: 1 randomized double blinded study, 1 randomized open label study, and 1 case 
analysis comparing symptom reduction of gastroparesis after the intervention of nasal and oral 
metoclopramide compared to placebo controls. These sources were found using PubMed and 
OVID. 
 
Outcomes Measured: Patients graded their symptoms on a scale and graded the severity of each 
symptom after the use of nasal and oral metoclopramide. The studies gave patients different 
scales to measure the severity of each symptom which included a Symptom Assessment 
Questionnaire (SAQ), Gastroparesis Cardinal Symptom Index Daily Diary, and a Clinical Patient 
Grading Assessment Scale (CPGAS).5,6,7  
 
Results: Conclusively, the studies did not show a reduction in symptoms after the intervention 
for gastroparesis in diabetic patients. Only one study demonstrated symptom reduction to be 
statistically significant while the other two studies did not.  
 
Conclusions: The use of metoclopramide did not show an improvement in gastroparesis 
symptoms as assessed by patients after the use of the medication from these studies. More RCT 
need to be done to prove this scientifically rather than through patient report due to bias or 
misunderstanding of scoring and through a trial using same comparison groups for a longer 
duration.  
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INTRODUCTION 
 
 Diabetes is the seventh leading cause of death in the United States and is prevalent in 
about 30.3 million Americans as of 2015.1 Diabetes as the primary medical condition results in 
34.6 million health care visits in the past year.1 The health care cost of a diabetes in 2017 in the 
United States was about $327 billion.1 Type 1 Diabetes is caused by a deficiency in insulin due 
to autoantibodies that form and attack the pancreatic islet beta cells that develops usually before 
the age of 20, resulting in hyperglycemia. Type 2 diabetes is mainly due to insulin resistance, 
insulin insufficiency, and elevated hepatic glucose production over time, also resulting in 
hyperglycemia, and commonly seen with obesity.1 The prevalence of diabetes is increasing 
drastically with 50 to 65% of patients with diabetes mellitus also having a diagnosis of 
gastroparesis.2 Diabetic gastroparesis is more prevalent in type 1 diabetics, but it is also seen in 
type 2 diabetics as well.  
 Gastroparesis is delayed gastric emptying that is seen in both type 1 and type 2 diabetes. 
This results in nausea, vomiting, belching, abdominal pain, heart burn, and early satiety. The 
exact etiology of diabetic gastroparesis is unknown and there is no ultimate cure other than to 
provide some relief of symptoms with changes in diet and using certain medications such as 
metoclopramide.3 It is suggested that gastroparesis occurs due to damage to the vagus nerve 
which controls the movement of food through the digestive tract.3  
 Metoclopramide, a prokinetic, increases muscle contractions in the digestive tract. Other 
than gastroparesis, Metoclopramide’s other uses involve the treatment of heartburn caused by 
gastroesophageal reflux disease.3,4 Other treatments to manage gastroparesis include controlling 
diet which is usually the initial step. Fatty, spicy, and acidic foods, and carbonated drinks should 
be avoided.4 This, however, only works for mild cases of gastroparesis. Hydration is key in 
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patients who have vomiting symptoms. Nutritional deficiencies can also arise in this specific 
group of patients due to vomiting episodes and resistance to eat due to nausea. Due to these side 
effects of gastroparesis, replenishing micronutrients is essential. Other treatments for targeting 
other symptoms of gastroparesis include erythromycin, prochlorperazine, diphenhydramine, and 
ondansetron. Refraining from smoking is also insisted in gastroparesis patients. A 
nonconventional method includes acupuncture.4 Lastly, surgical treatment is reserved for patients 
who are unable to tolerate any types of food at all, which includes a jejunostomy tube.4 
 Diabetic patients struggle to maintain their quality of life with trying to balance diet, 
exercise, frequent doctor and pharmacy visits, insurance difficulties, and treatment adherence. 
Diabetes causes an increase in glucose in the body which delays emptying food from the 
stomach to the intestines which causes an arousal of symptoms. Gastroparesis adds further stress 
to a diabetic patient decreasing their quality of life furthermore. Since so much of the population 
if affected by diabetes and its immense list of complications, one being gastroparesis, it is 
essential for all healthcare providers to be knowledgeable so that proper guidance and effective 
treatment can be recommended for patients. This paper evaluates the effectiveness of 
metoclopramide for gastroparesis symptoms in diabetic patients, compared to nasal and oral 
forms of metoclopramide, as well as to the placebo control.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not is 
Metoclopramide effective in treating symptoms in diabetic gastroparesis? 
METHODS 
 This selective EBM review examined three studied which included 1 randomized double 
blinded study, 1 randomized open label study, and 1 open label case analysis comparing 
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symptom reduction of gastroparesis after the intervention of nasal and oral metoclopramide 
compared to placebo controls.5,6,7 The population included male and female patients older than 
18 years of age with a diagnosis of diabetes and gastroparesis. The intervention used in each of   
the studies was metoclopramide 14 mg and 20 mg nasal spray, as well as oral metoclopramide 10 
mg.5,6,7 Treatment groups received the nasal metoclopramide and the control group received the 
oral metoclopramide or placebo. The outcomes measured in each was whether there was a 
reduction in symptoms of gastroparesis after the intervention of metoclopramide for patients 
experiencing gastroparesis, furthermore if there was a better prognosis when comparing nasal to 
oral metoclopramide. All studies were published in the English language and were published 
between 2012 through 2014. The studies were found using two keywords “Gastroparesis” and 
“Metoclopramide” through PubMed and OVID. Articles were selected based on their relevance 
to the clinical question and had patient oriented outcomes (POEMS). Inclusion criteria included 
studies that were randomized, controlled, double blind, open label, and case analysis studies that 
measured the effectiveness of metoclopramide in gastroparesis patients. It also included patients 
taking metoclopramide or patients who had a diagnosis of gastroparesis. Articles written over 10 
years ago and patients under the age of 18 were excluded as part of the exclusion criteria. 
Statistics reported were p-values, relative benefit increase (RBI), numbers needed to treat (NNT), 
and absolute benefit increase (ABI). The demographics and characteristics of the individuals 
included in these studies are displayed in Table 1. 
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Table 1 – Demographics & Characteristics of included studies
Study Type  # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria  
W/D Interventions 
Parkman5 
HP, 2012 
Open -
Label 
Case 
Analysi
s 
100 >18 
years of 
age  
Patients 18 years of age 
and older receiving or 
having received 
metoclopramide treatment 
as part of their regular 
clinical care, and able to 
provide informed consent 
to participate in the study. 
Patients with 
a fasting 
glucose 
>280 mg/dL 
did not meet 
the standards 
to be a 
candidate.  
0 Metoclopramide  
Parkman6 
HP, 2015 
Double 
Blind 
RCT 
225 18-75 
years of 
age 
18 to 75 years of age with 
type 1 or type 2 DM with 
a diagnosis of 
gastroparesis, and who 
had a mean daily GCSI–
DD score between 2-4 for 
the 7 days before the 
randomization visit (day 
0) and were willing to 
discontinue treatment for 
diabetic gastroparesis.  
Subjects 
with a mean 
GCSI–DD 
total score of 
less than 2.0 
or greater 
than 4.0 
during the 
washout 
period were 
excluded. 
2 Metoclopramide 
14 mg Nasal 
Spray  
Parkman7 
H, 2014 
Open-
Label 
RCT 
89 18-82 
years of 
age 
Men, non-pregnant, non-
lactating women aged 18 
years or older with a 
diagnosis of Type 1 or 
Type 2 diabetes and 
diabetic gastroparesis 
who were willing to 
discontinue current 
gastroparesis treatment 
for at least 7 days before 
dosing until the end of the 
6-week study. Baseline 
requirement of a score 
between 8-20 on 
SAQ and IAQ scale with 
at least 2/6 symptoms on 
the SAQ and IAQ rated 
moderate or higher (≥2) 
for frequency and severity 
was required.  
 
Patients with 
abnormal 
chemistry or 
hematology 
parameters 
(with the 
exception of 
plasma 
glucose), and 
an estimated 
creatinine 
clearance of  
<40 mL/min 
were 
excluded.  
7 Metoclopramide 
20 mg Nasal 
Spray 
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OUTCOMES MEASURED 
 Throughout these studies, patients graded their symptoms on a scale based on change 
whether they improved, worsened, or stayed the same after the use of metoclopramide. In one 
study, a Clinical Patient Grading Assessment Scale (CPGAS) was used.5 In another study, 
patients kept track of their symptoms by recording the data in a Gastroparesis Cardinal Symptom 
Index Diary.6 In the last study, investigators assessed patient’s symptoms and their severity 
through an Investigator’s Assessment Questionnaire. after patients had filled out a Symptom 
Assessment Questionnaire (SAQ).7 
RESULTS 
 All three studies used an intervention of metoclopramide whether it was in a nasal or oral 
form. Two studies used nasal metoclopramide as interventions comparing it to placebo or a 
control. One study, a case analysis, used an intervention of metoclopramide but had no control or 
comparison group. All studies used participants above the age of 18 including men and women 
with gastroparesis symptoms. In all three studies, patients under the age of 18 were excluded. 
Subjects with high glucose readings were also excluded to maintain proper glycemic levels, since 
a side effect of metoclopramide includes hyperglycemia.5,6,7 Parkman’s 2015 double blind RCT 
excluded patients whose gastroparesis symptoms were too mild, as metoclopramide was not 
needed, or to severe, to maintain safety form adverse effects.6 In this double blind RCT, two 
subjects did not complete the experiment due to withdrawal of consent and another subject 
having a history of chronic pancreatitis.6  In Parkman’s 2014 open label RCT, 92.1% subjects 
completed the study, and seven subjects withdrew from the study due to side effects.7 
 Parkman’s 2014 RCT open label study evaluated the change in symptoms from baseline 
with the intervention of nasal metoclopramide 20 mg and compared it to oral metoclopramide 10 
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mg at six study sites across the United States.7 The intervention of nasal metoclopramide 10 mg 
was also used in this study, however, this paper will solely focus on the nasal metoclopramide 20 
mg compared to the oral metoclopramide 10 mg. Eighty-nine diabetic participants were assessed 
in this study for six weeks and were given metoclopramide four times a day. A symptom 
assessment questionnaire (SAQ) was used where patients rated the symptom severity before, 
during, and after the treatment. Symptoms included nausea, vomiting, anorexia, bloating, early 
satiety, and meal tolerance. A score between 0 to 4 was given. Then, the investigator’s 
assessment questionnaire (IAQ) was used by investigators to rate the severity for each patient as 
well by interviewing each patient. The mean total symptom score (TSS) reduced about 13 points 
for nearly all patients from baseline after 1 week of treatment. The data showed that 97.1% of the 
participants who received nasal metoclopramide 20 mg and 88.9% who received oral 
metoclopramide 10 mg responded to the treatment.7 The nasal 20 mg metoclopramide group had 
a confidence interval of (-7.1,-0.5) with a p-value of 0.026 as shown in Table 2.7 
Table 2: Comparison of Efficacy through Mean Change from Baseline to Outcome 
Treatment 
Metoclopramide 
N Baseline 
Mean 
Mean change 
from baseline 
95% CI p-value 
Nasal 20 mg7 35 21.3 -18.0 (-7.1, -0.5) 0.026 
Oral 10 mg7 18 22.9 -14.3 N/A N/A 
The data from the study was calculated to get the number needed to treat (NNT) which was 13 as 
shown in Table 3. 13 people need to be treated with metoclopramide in order to have one 
successful outcome in reducing symptoms of gastroparesis.  
Table 3: Statistical Analysis of Parkman’s Efficacy in Improving Symptoms 
NNT RBI ABI 
13 0.092 0.082 
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 Parkman’s 2015 RCT double blinded study used 14 mg nasal metoclopramide as its 
intervention and compared it to a placebo. This study used participants between the age of 18 to 
75 who also had a diagnosis of diabetes and a gastroparesis similar to Parkman’s 2014 RCT open 
label study. These 225 participants were monitored in the United States at various 
gastroenterology or mixed specialty practices that treated gastroparesis.6 Four symptoms were 
monitored throughout this study which included nausea, bloating, early satiety, and upper 
abdominal pain.6 This study also used nasal metoclopramide 10 mg, however, this paper will 
focus only on the placebo compared to the nasal 14 mg metoclopramide. Subjects recorded 
symptom severity on the Gastroparesis Cardinal Symptom Index Daily Diary.6 Compliance of 
males completing daily diary recordings was 90% and 86% for females.6 They were required to 
grade each symptom from 0 to 5. The study did not show a confidence interval however a p-
value of 0.3005 comparing the placebo to the 14mg metoclopramide was reported which is not 
statistically significant.6 The change from baseline to end of the study showed a mean and 
standard deviation of -1.2(0.94) compared to the placebo -1.0(0.89).6 This study also focused on 
the changes in symptoms between males and females. Women with nasal metoclopramide had 
more improvements with symptoms reported by the change from baseline to week 4 with a mean 
and standard deviation of -1.3(0.98) as compared to males -0.9(0.78). Males seemed to have a 
greater response to the placebo with a mean and standard deviation of -1.4(0.98).6 This data is 
shown in Table 4.  
Table 4: Mean Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD) Total Score 
Change from Baseline to Week 46 
 Placebo (N=95) MCP 14 mg Nasal (N=96) 
Baseline, mean (SD) 2.8(0.57) 2.8(0.062) 
Week 4, mean (SD) 1.8(1.00) 1.7(0.90) 
Change from baseline to week 4 -1.0(0.89) -1.2(0.94) 
p-value N/A 0.3005 
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Women -Baseline, mean (SD) 2.7 (0.54) 2.9(0.62) 
Male -Baseline, mean (SD) 2.9(0.63) 2.5(0.56) 
Women - Week 4, mean (SD) 1.9 (1.02) 1.7(0.94) 
Men - Week 4, mean (SD) 1.4(0.84) 1.7(0.79) 
Women - Change from baseline to week 4 -0.8(0.79) -1.3(0.98) 
Men - Change from baseline to week 4 -1.4(0.98) -0.9(0.78) 
 
 The last study, Parkman’s case analysis, focused on 100 participants who were regularly 
taking metoclopramide for gastroparesis, 34 of these patients had a diagnosis of diabetes.5 
Patients assessed their symptoms using the Clinical Patient Grading Assessment Scale from a 
score of -3 to 3. The study stated that 53% of the participants had improvement with taking 
metoclopramide with a p-value of 0.83.5 This study further investigated side effects and found 
that 64% of the participants reported side effects to metoclopramide.5 Side effects included 
anxiety, akathisia, fatigue, tremors, depression, dystonia, seizures, and tardive dyskinesia. The 
study reported that side effects were often more reported in the 77% of non-diabetic patients 
rather than diabetic gastroparesis patients.5  
 The other two studies also reported side effects of headaches, fatigue, nausea, vomiting,  
 
dysgeusia, drowsiness, and restlessness. Parkman’s RCT open label study found an increase in  
 
side effects in oral 10 mg metoclopramide compared to nasal 20 mg metoclopramide. There were  
 
no reported deaths in any of the studies. The greatest side effects reported conclusively from all  
 
three studies were those affecting the central nervous system. The complaints reported by  
 
patients in each study listed by frequency are shown more thoroughly by various body systems in  
 
Table 5. 
Table 5: Adverse Effects reported by frequency of participants in each study 
Adverse Effects Parkman’s RCT 
Open Label7 
Parkman’s RCT 
Double Blind6 
Parkman’s Case 
Analysis5 
Nervous System (HA, Dizziness, 
akathisia, tremors, tardive 
dyskinesia, dystonia, confusion, 
seizure, dysgeusia) 
1 24 31 
Psychiatric 
(depression, anxiety) 
0 0 15 
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Gastrointestinal (diarrhea, 
vomiting, nausea) 
3 6 0 
Metabolic (hyperglycemia, 
hypoglycemia) 
0 6 0 
Respiratory (cough, epistaxis, 
cough, rhinorrhea, throat 
discomfort) 
0 14 0 
Infections (URI) 0 3  
General (fatigue) 0 6 9 
Skin (rash) 1 0  
Miscellaneous 0 0 9 
  
DISCUSSION 
 There were many limitations seen in these studies. All three studies used questionnaires 
for patients to fill out as their main source of composing and collecting data. The scoring range 
scale in each of the studies was different making it difficult to align the data together. 
 Metoclopramide, brand name Reglan, is a dopamine 2 receptor antagonist, a 5-HT4 
agonist, and a weak HT3 receptor agonist, which the FDA has approved for the treatment for 
gastroparesis for 12 weeks, longer if the benefits are greater than the risks.5 However, 
Metoclopramide has a black box warning for tardive dyskinesia.3 Parkman’s 2012 case analysis 
also failed to report the duration of the study making it not a reliable source to administer 
treatment in a patient. Furthermore, the open label case analysis reported adverse effects of 
tardive dyskinesia and many other central nervous system adverse side effects. CNS side effects 
cause hesitation in administering treatment in patients, especially those that involve movement 
disorders like tardive dyskinesia.  
 Metoclopramide is the only approved treatment for gastroparesis by the FDA and is 
easily accessible to most patients through health insurances.3 It is also easily available 
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throughout the United States with a prescription. Oral tablet form is more common than nasal 
metoclopramide.4 Injection form is also available.  
CONCLUSION 
 Other resources have shown that metoclopramide is the only approved treatment for  
 
gastroparesis. However, these three studies did not show collective data to show that  
 
metoclopramide is effective in treating symptoms in gastroparesis. These studies also showed  
 
adverse effects of metoclopramide, some of which included seizures, tardive dyskinesia, and 
other movement disorders which makes treating a patient with this drug highly questionable. 
Further investigation showed that only 2 patients developed tardive dyskinesia from Parkman’s 
2012 case analysis.5 The studies showed that metoclopramide is safe and moderately tolerable in 
most patients, and less side effects when used in diabetic patients. No deaths occurred in the 
trials either. This drug has FDA approval which allows for more use by physicians and less risks 
when used in patients, however, the data conclusively in all studies do not support evidence to 
prove the efficacy of metoclopramide. Parkman’s 2012 case analysis had no comparison group 
and used any dose of metoclopramide and any duration of time metoclopramide was being used 
by patients. Parkman’s 2015 study compared to a placebo while Parkman’s 2012 group 
compared to another dose of metoclopramide. There was no common comparison group in any 
of the studies and only Parkman’s 2014 study showed to be statistically significant.  Further 
studies should be conducted specifically in groups of people who have developed tardive 
dyskinesia, seizures, akathisia, or other CNS adverse effects to see if the therapeutic benefit of 
metoclopramide does in fact outweigh the risks, and trials that are longer in duration. 
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